Genprex Inc
$ 1.09
-5.63%
21 Apr - close price
- Market Cap 10,446,800 USD
- Current Price $ 1.09
- High / Low $ 1.32 / 1.04
- Stock P/E N/A
- Book Value 3.78
- EPS -17.40
- Next Earning Report 2026-05-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -1.36 %
- ROE -3.39 %
- 52 Week High 55.00
- 52 Week Low 1.04
About
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company is headquartered in Austin, Texas.
Analyst Target Price
$7.50
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-27 | 2025-11-14 | 2025-08-14 | 2025-05-13 | 2025-03-31 | 2024-11-12 | 2024-08-09 | 2024-05-15 | 2024-02-26 | 2023-11-14 | 2023-08-21 | 2023-05-22 |
| Reported EPS | -1.1515 | -5 | -8.47 | -0.26 | -0.4242 | -1.23 | -3 | -3.69 | -3.96 | -0.13 | -0.15 | -0.19 |
| Estimated EPS | None | -0.65 | -0.74 | -2.54 | -0.39 | -1.93 | -2.3 | -2.54 | -3.93 | -0.11 | -0.12 | -0.12 |
| Surprise | 0 | -4.35 | -7.73 | 2.28 | -0.0342 | 0.7 | -0.7 | -1.15 | -0.03 | -0.02 | -0.03 | -0.07 |
| Surprise Percentage | None% | -669.2308% | -1044.5946% | 89.7638% | -8.7692% | 36.2694% | -30.4348% | -45.2756% | -0.7634% | -18.1818% | -25% | -58.3333% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-11 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: GNPX
2026-04-21 13:39:41
Genprex (GNPX) has announced a new Sponsored Research Agreement with The University of Texas MD Anderson Cancer Center. This collaboration aims to study biomarkers that could predict patient response to Reqorsa Gene Therapy. Reqorsa is Genprex's leading drug candidate currently under development for treating non-small cell lung cancer and small cell lung cancer.
2026-04-21 11:39:41
Genprex announced a research agreement with UT MD Anderson to study biomarkers that could predict responses to its REQORSA gene therapy for NSCLC and SCLC. Preclinical data suggest TROP2 and PTEN as potential biomarkers for patient selection, which could optimize outcomes in ongoing Acclaim-1 and Acclaim-3 trials. Both trials have shown promising early results with REQORSA in combination with Tagrisso and Tecentriq, respectively.
2026-04-21 10:39:41
Genprex, Inc. announced a new Sponsored Research Agreement with The University of Texas MD Anderson Cancer Center to study biomarkers, specifically TROP2 and PTEN, that may predict patient response to its lead gene therapy candidate, Reqorsa®. This research aims to refine patient selection strategies for Genprex's Acclaim-1 and Acclaim-3 clinical trials in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) and optimize clinical outcomes. The agreement highlights Genprex's commitment to precision oncology and developing tailored treatment options for lung cancer patients with unmet medical needs.
2026-04-21 10:39:41
Genprex (NASDAQ: GNPX) has announced a new Sponsored Research Agreement with The University of Texas MD Anderson Cancer Center to study biomarkers (TROP2 and PTEN) that could predict patient response to its Reqorsa Gene Therapy for lung cancer. The company also provided updates on its Acclaim-1 and Acclaim-3 Phase 1/2 clinical trials, reporting no dose-limiting toxicities and signs of efficacy, including prolonged progression-free survival and partial remissions in some patients. This partnership and clinical progress aim to refine patient selection and optimize outcomes for non-small cell and small cell lung cancer treatments.
2026-04-20 12:10:22
Genprex Inc. announced the presentation of preclinical data for its lead drug candidate, Reqorsa Gene Therapy, at the American Association for Cancer Research Annual Meeting. The studies identified TROP2 and PTEN as potential biomarkers for predicting patient response to Reqorsa in non-small cell lung cancer, and showed promise in overcoming resistance to ALK inhibitors in mouse models. The company, which is evaluating Reqorsa in two clinical trials, also recently secured new patents in Japan and Europe for its gene therapy in combination with immunotherapy antibodies.
2026-04-17 20:09:40
Genprex is asking shareholders to approve a reverse stock split at a ratio between 1:5 and 1:50, along with an amended equity incentive plan, election of two Class III directors, ratification of their independent auditor, an advisory vote on executive compensation, and an adjournment proposal. The company aims to maintain its Nasdaq listing and enhance investor interest, but warns that a reverse split does not guarantee increased stock price or continued Nasdaq compliance. The annual meeting, to be held virtually on June 18, 2026, will also address specific executive compensation details and corporate governance matters.
